Terms: = Pancreatic cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Prognosis
373 results:
1. Unlocking the Role of Age-Related Changes to Fibroblasts in pancreatic cancer.
Isaacson A; Barki D; Scherz-Shouval R
Cancer Res; 2024 Apr; 84(8):1185-1187. PubMed ID: 38616657
[TBL] [Abstract] [Full Text] [Related]
2. Nuclear MAST4 Suppresses FOXO3 through Interaction with akt3 and Induces Chemoresistance in pancreatic Ductal Carcinoma.
Fujiwara-Tani R; Sasaki T; Bhawal UK; Mori S; Ogata R; Sasaki R; Ikemoto A; Kishi S; Fujii K; Ohmori H; Sho M; Kuniyasu H
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612866
[TBL] [Abstract] [Full Text] [Related]
3. IFNα-induced BST2
Zheng C; Wang J; Zhou Y; Duan Y; Zheng R; Xie Y; Wei X; Wu J; Shen H; Ye M; Kong B; Liu Y; Xu P; Zhang Q; Liang T
Cell Rep; 2024 Apr; 43(4):114088. PubMed ID: 38602878
[TBL] [Abstract] [Full Text] [Related]
4. Frizzled class receptor 5 contributes to ovarian cancer chemoresistance through aldehyde dehydrogenase 1A1.
Xia Y; Wang S; Sun Y; Wang W; Chang S; Zhang Z; Zhao C
Cell Commun Signal; 2024 Mar; 22(1):194. PubMed ID: 38539211
[TBL] [Abstract] [Full Text] [Related]
5. PELI1: key players in the oncogenic characteristics of pancreatic cancer.
Fei X; Zhu C; Liu P; Liu S; Ren L; Lu R; Hou J; Gao Y; Wang X; Pan Y
J Exp Clin Cancer Res; 2024 Mar; 43(1):91. PubMed ID: 38528516
[TBL] [Abstract] [Full Text] [Related]
6. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
7. Activation of the PI3K/akt signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib.
Ge W; Wang Y; Quan M; Mao T; Bischof EY; Xu H; Zhang X; Li S; Yue M; Ma J; Yang H; Wang L; Yu Z; Wang L; Cui J
Mol Cancer; 2024 Mar; 23(1):48. PubMed ID: 38459558
[TBL] [Abstract] [Full Text] [Related]
8. Nomogram incorporating prognostic immune-inflammatory-nutritional score for survival prediction in pancreatic cancer: a retrospective study.
Yang J; Zhou H; Li H; Zhao F; Tong K
BMC Cancer; 2024 Feb; 24(1):193. PubMed ID: 38347528
[TBL] [Abstract] [Full Text] [Related]
9. The emerging roles of CEACAM6 in human cancer (Review).
Wu G; Wang D; Xiong F; Wang Q; Liu W; Chen J; Chen Y
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38240103
[TBL] [Abstract] [Full Text] [Related]
10. Dichotomous role of the serine/threonine kinase MAP4K4 in pancreatic ductal adenocarcinoma onset and metastasis through control of akt and ERK pathways.
Juin A; Spence HJ; Machesky LM
J Pathol; 2024 Apr; 262(4):454-466. PubMed ID: 38229581
[TBL] [Abstract] [Full Text] [Related]
11. NUDT21 interacts with NDUFS2 to activate the PI3K/akt pathway and promotes pancreatic cancer pathogenesis.
Huang XD; Chen YW; Tian L; Du L; Cheng XC; Lu YX; Lin DD; Xiao FJ
J Cancer Res Clin Oncol; 2024 Jan; 150(1):8. PubMed ID: 38195952
[TBL] [Abstract] [Full Text] [Related]
12. EPYC functions as a novel prognostic biomarker for pancreatic cancer.
Yang Z; Li H; Hao J; Mei H; Qiu M; Wang H; Gao M
Sci Rep; 2024 Jan; 14(1):719. PubMed ID: 38184732
[TBL] [Abstract] [Full Text] [Related]
13. Therapeutic potential of SHCBP1 inhibitor AZD5582 in pancreatic cancer treatment.
Ma Z; Gu Q; Dai Y; Wang Q; Shi W; Jiao Z
Cancer Sci; 2024 Mar; 115(3):820-835. PubMed ID: 38151993
[TBL] [Abstract] [Full Text] [Related]
14. IgG4-related pancreatobiliary diseases could be associated with onset of pancreatobiliary cancer: A multicenter cohort study.
Kurita Y; Kubota K; Fujita Y; Tsujino S; Sekino Y; Kasuga N; Iwasaki A; Iwase M; Izuka T; Kagawa K; Tanida E; Yagi S; Hasegawa S; Sato T; Hosono K; Kobayashi N; Ichikawa Y; Nakajima A; Endo I
J Hepatobiliary Pancreat Sci; 2024 Mar; 31(3):173-182. PubMed ID: 38124014
[TBL] [Abstract] [Full Text] [Related]
15. Neuromedin U regulates the anti-tumor activity of CD8
Zheng R; Wang S; Wang J; Zhou M; Shi Q; Liu B
Cancer Sci; 2024 Feb; 115(2):334-346. PubMed ID: 38071753
[TBL] [Abstract] [Full Text] [Related]
16. LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability.
Han L; Jiang Y; Shi M; Gan L; Wu Z; Xue M; Zhu Y; Xiong C; Wang T; Lin X; Shen B; Jiang L; Chen H
J Transl Med; 2023 Nov; 21(1):838. PubMed ID: 37990271
[TBL] [Abstract] [Full Text] [Related]
17. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
[TBL] [Abstract] [Full Text] [Related]
18. USP11 potentiates HGF/akt signaling and drives metastasis in hepatocellular carcinoma.
Chen J; Ning D; Du P; Liu Q; Mo J; Liang H; Zhang W; Zhang M; Jiang L; Zhang B; Chen X
Oncogene; 2024 Jan; 43(2):123-135. PubMed ID: 37973952
[TBL] [Abstract] [Full Text] [Related]
19. Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity.
Bhoopathi P; Kumar A; Pradhan AK; Maji S; Mannangatti P; Windle JJ; Subler MA; Zhang D; Vudatha V; Trevino JG; Madan E; Atfi A; Sarkar D; Gogna R; Das SK; Emdad L; Fisher PB
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935566
[TBL] [Abstract] [Full Text] [Related]
20. akt and mTOR expression in human pancreatic ductal adenocarcinoma. Relevance for tumor biology.
Handra-Luca A
Pathol Res Pract; 2023 Nov; 251():154878. PubMed ID: 37890271
[TBL] [Abstract] [Full Text] [Related]
[Next]
